Board okays Q1 FY27 results; consolidated revenue up about 51% YoY

Revenue growth above 20%Results View source PDF Explain this filing

3BBLACKBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.0%Reaction day

₹1224.00

prior close

₹1181.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-4.1% vs market

Healthcare Service Provider peers, median of 26sector-2.0%-2.0% vs sector

On the reaction day the stock moved 4.1 pts less than Nifty Microcap 250 and 2.0 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-0.4

15m

-1.1

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.0+0.1-4.1-2.0-2.0

Next day

-6.4+0.2-6.6-0.3-6.1

-6.0+0.6-6.6-0.3-5.8

-6.3-0.0-6.3-3.7-2.6

-5.2+0.5-5.7-2.3-3.0

-2.1+0.8-2.9-2.8+0.7

+2.9+0.6+2.4-0.4+3.4

15d

+20.6+1.3+19.3+0.4+20.2

+10.7-1.4+12.1-1.0+11.7

+18.7-0.6+19.3-5.8+24.5

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 results on Aug 13, 2026. Standalone revenue rose 12.7% YoY to Rs 2,294.52L, PAT up 13.3% to Rs 1,411.21L (EPS Rs 16.41). Consolidated revenue surged about 50.6% to Rs 3,349.08L led by diagnostic kits segment, though PAT fell about 29% to Rs 897.84L (EPS Rs 10.48). Agrochemical revenue declined. Board also appointed Cost Auditor for FY27.

Likely market impact

Strong topline growth from diagnostic segment, but consolidated profit declined. Watch segment mix and operating costs.